Amneal Pharmaceuticals stock gained 1.15 percent after UBS kept Buy

Published on 10/04/2026 at 23:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set a USD 25.00 target for Amneal Pharmaceuticals stock on October 1, while second-quarter revenue reached USD 796.2 million. Adjusted EPS beat consensus.

AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals stock (ISIN US03168L1052) closed at USD 20.30 on Nasdaq on October 2, 2026, up 1.15 percent from USD 20.07. The latest analyst signal came on October 1, when Investing.com reported that UBS reiterated a Buy rating and a USD 25.00 price target.

UBS keeps focus on hormone therapy

UBS identified Amneal's hormone replacement therapy patch franchise as a near-term value driver and kept its target at USD 25.00 on October 1, 2026. The target stands 23.2 percent above the October 2 closing price, a gap that places the analyst view above the stock's latest market valuation.

The same report linked the thesis to expanded manufacturing capacity and biosimilar growth. It also cited Amneal's second-quarter performance and updated outlook as support for the rating, while execution on launches and regulatory outcomes remain material variables.

Q2 revenue reaches USD 796.2 million

Amneal reported second-quarter 2026 revenue of USD 796.2 million and adjusted EPS of USD 0.30, compared with consensus EPS of USD 0.24, according to MarketBeat on September 26, 2026. The USD 0.06 adjusted EPS beat shows why the recent analyst debate centers on the conversion of new products into recurring earnings.

Second-quarter revenue also rose 10 percent from USD 725 million in the year-earlier quarter, while net income increased to USD 58 million from USD 22 million, Yahoo Finance reported on September 4, 2026. Management raised full-year 2026 revenue guidance to USD 3.10 billion-USD 3.20 billion, adding a second quantified checkpoint for the growth case.

Stock remains below yearly high

Amneal's USD 20.30 close on October 2, 2026, was 4.2 percent below the 52-week high of USD 21.18 and 112.3 percent above the 52-week low of USD 9.56. The company had a market capitalization of USD 6.5 billion and trading volume of 2,815,676 shares on that session.